NCT06091423View on ClinicalTrials.gov

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

November 25, 2025

Study Completion Date

November 25, 2026

Conditions
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

XELOX combined with Fruquintinib and Sintilimab

XELOX:Capecitabine：800mg/m2, po, bid, d1-14。Oxaliplatin：130mg/m2，ivgtt 2-6h，d1，q3w; Fruquintinib: 5 mg/d，qd po，d1-14，q3w; Sintilimab: 200mg d1, q3w

Trial Locations (1)

Unknown

RECRUITING

Jiangsu Province Hospita, Nanjin

All Listed Sponsors
lead

Xiaofeng Chen

OTHER